Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern

Zane T. Hammoud, Lacey Dobrolecki, Kenneth Kesler, Emad Rahmani, Karen Rieger, Linda H. Malkas, Robert J. Hickey

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Currently, endoscopic biopsy is the only method used to diagnose esophageal adenocarcinoma. Using surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, we sought to identify a potentially diagnostic serum protein pattern that can serve as a reliable blood test for the diagnosis of esophageal adenocarcinoma. In addition, we sought to identify potential biomarkers for esophageal adenocarcinoma. Methods: Whole serum was collected using standard techniques from subjects with a known diagnosis of esophageal adenocarcinoma as well as from subjects without any known esophageal disease. The samples were spotted onto a hydrophobic (H50) and immobilized metal affinity (IMAC30) chip surface and allowed to incubate. All samples were run in duplicate. After several washes, matrix was added and a mass range of 1500 to 30000 daltons was analyzed by SELDI-Time-of-Flight mass spectroscopy. Statistical analysis was performed using Biomarker Pattern Software (Bio-Rad Laboratories, Hercules, CA). Results: For the H50 analysis, 3 peaks were identified that correctly diagnosed 42 of 43 cancers and 10 of 11 normals. For the IMAC30, 4 peaks were identified that correctly diagnosed 50 of 50 cancers and 10 of 10 normals. Conclusions: Serum proteomic pattern shows great promise in the diagnosis of esophageal adenocarcinoma. This technology may lead to the development of a noninvasive screening test as well as to the identification of potential novel biomarkers for esophageal adenocarcinoma.

Original languageEnglish
Pages (from-to)384-392
Number of pages9
JournalAnnals of Thoracic Surgery
Volume84
Issue number2
DOIs
StatePublished - Aug 2007

Fingerprint

Proteomics
Adenocarcinoma
Serum
Biomarkers
Lasers
Esophageal Diseases
Technology
Protein Array Analysis
Hematologic Tests
Blood Proteins
Mass Spectrometry
Neoplasms
Software
Metals
Biopsy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern. / Hammoud, Zane T.; Dobrolecki, Lacey; Kesler, Kenneth; Rahmani, Emad; Rieger, Karen; Malkas, Linda H.; Hickey, Robert J.

In: Annals of Thoracic Surgery, Vol. 84, No. 2, 08.2007, p. 384-392.

Research output: Contribution to journalArticle

Hammoud, Zane T. ; Dobrolecki, Lacey ; Kesler, Kenneth ; Rahmani, Emad ; Rieger, Karen ; Malkas, Linda H. ; Hickey, Robert J. / Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern. In: Annals of Thoracic Surgery. 2007 ; Vol. 84, No. 2. pp. 384-392.
@article{00c50438e18d44ef9215e7d18e5e7299,
title = "Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern",
abstract = "Background: Currently, endoscopic biopsy is the only method used to diagnose esophageal adenocarcinoma. Using surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, we sought to identify a potentially diagnostic serum protein pattern that can serve as a reliable blood test for the diagnosis of esophageal adenocarcinoma. In addition, we sought to identify potential biomarkers for esophageal adenocarcinoma. Methods: Whole serum was collected using standard techniques from subjects with a known diagnosis of esophageal adenocarcinoma as well as from subjects without any known esophageal disease. The samples were spotted onto a hydrophobic (H50) and immobilized metal affinity (IMAC30) chip surface and allowed to incubate. All samples were run in duplicate. After several washes, matrix was added and a mass range of 1500 to 30000 daltons was analyzed by SELDI-Time-of-Flight mass spectroscopy. Statistical analysis was performed using Biomarker Pattern Software (Bio-Rad Laboratories, Hercules, CA). Results: For the H50 analysis, 3 peaks were identified that correctly diagnosed 42 of 43 cancers and 10 of 11 normals. For the IMAC30, 4 peaks were identified that correctly diagnosed 50 of 50 cancers and 10 of 10 normals. Conclusions: Serum proteomic pattern shows great promise in the diagnosis of esophageal adenocarcinoma. This technology may lead to the development of a noninvasive screening test as well as to the identification of potential novel biomarkers for esophageal adenocarcinoma.",
author = "Hammoud, {Zane T.} and Lacey Dobrolecki and Kenneth Kesler and Emad Rahmani and Karen Rieger and Malkas, {Linda H.} and Hickey, {Robert J.}",
year = "2007",
month = "8",
doi = "10.1016/j.athoracsur.2007.03.088",
language = "English",
volume = "84",
pages = "384--392",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern

AU - Hammoud, Zane T.

AU - Dobrolecki, Lacey

AU - Kesler, Kenneth

AU - Rahmani, Emad

AU - Rieger, Karen

AU - Malkas, Linda H.

AU - Hickey, Robert J.

PY - 2007/8

Y1 - 2007/8

N2 - Background: Currently, endoscopic biopsy is the only method used to diagnose esophageal adenocarcinoma. Using surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, we sought to identify a potentially diagnostic serum protein pattern that can serve as a reliable blood test for the diagnosis of esophageal adenocarcinoma. In addition, we sought to identify potential biomarkers for esophageal adenocarcinoma. Methods: Whole serum was collected using standard techniques from subjects with a known diagnosis of esophageal adenocarcinoma as well as from subjects without any known esophageal disease. The samples were spotted onto a hydrophobic (H50) and immobilized metal affinity (IMAC30) chip surface and allowed to incubate. All samples were run in duplicate. After several washes, matrix was added and a mass range of 1500 to 30000 daltons was analyzed by SELDI-Time-of-Flight mass spectroscopy. Statistical analysis was performed using Biomarker Pattern Software (Bio-Rad Laboratories, Hercules, CA). Results: For the H50 analysis, 3 peaks were identified that correctly diagnosed 42 of 43 cancers and 10 of 11 normals. For the IMAC30, 4 peaks were identified that correctly diagnosed 50 of 50 cancers and 10 of 10 normals. Conclusions: Serum proteomic pattern shows great promise in the diagnosis of esophageal adenocarcinoma. This technology may lead to the development of a noninvasive screening test as well as to the identification of potential novel biomarkers for esophageal adenocarcinoma.

AB - Background: Currently, endoscopic biopsy is the only method used to diagnose esophageal adenocarcinoma. Using surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, we sought to identify a potentially diagnostic serum protein pattern that can serve as a reliable blood test for the diagnosis of esophageal adenocarcinoma. In addition, we sought to identify potential biomarkers for esophageal adenocarcinoma. Methods: Whole serum was collected using standard techniques from subjects with a known diagnosis of esophageal adenocarcinoma as well as from subjects without any known esophageal disease. The samples were spotted onto a hydrophobic (H50) and immobilized metal affinity (IMAC30) chip surface and allowed to incubate. All samples were run in duplicate. After several washes, matrix was added and a mass range of 1500 to 30000 daltons was analyzed by SELDI-Time-of-Flight mass spectroscopy. Statistical analysis was performed using Biomarker Pattern Software (Bio-Rad Laboratories, Hercules, CA). Results: For the H50 analysis, 3 peaks were identified that correctly diagnosed 42 of 43 cancers and 10 of 11 normals. For the IMAC30, 4 peaks were identified that correctly diagnosed 50 of 50 cancers and 10 of 10 normals. Conclusions: Serum proteomic pattern shows great promise in the diagnosis of esophageal adenocarcinoma. This technology may lead to the development of a noninvasive screening test as well as to the identification of potential novel biomarkers for esophageal adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=34447580916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447580916&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2007.03.088

DO - 10.1016/j.athoracsur.2007.03.088

M3 - Article

VL - 84

SP - 384

EP - 392

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 2

ER -